ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
3 hedge funds and large institutions have $5K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 23 closing their positions.
89% less funds holding
Funds holding: 27 → 3 (-24)
99% less capital invested
Capital invested by funds: $405K → $5K (-$400K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$39.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$254K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$60K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15K |
| 4 |
VF
Virtu Financial
New York
|
-$15K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$13K |
IMUC Hedge Fund Activity: Q4 2018 in Review
3 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q4 2018, worth a combined $5K — down 99% from $405K a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of IMUC and 0 opened new positions — a net loss of 23 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Wedbush Securities, adding an estimated $39.4K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $254K sold.
- 3 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q4 2018, down from 27 in Q3 2018.
- Funds reported $5K of ImmunoCellular Therapeutics, Ltd. stock for Q4 2018, down 99% quarter-over-quarter.
- 0 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q4 2018 and 23 closed out, a net change of -23 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q4 2018 was Wedbush Securities, an estimated $39.4K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q4 2018 was Renaissance Technologies, an estimated $254K sold.
Based on aggregated 13F filings for Q4 2018.